New drug aims to stop neuroendocrine tumors from returning after surgery
NCT ID NCT07279532
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether the drug surufatinib, taken daily for 6 months after surgery, can prevent neuroendocrine tumors from coming back in high-risk patients. It will enroll 35 adults with stage III tumors (including G1, G2, and all G3 types). The main goal is to see how long patients stay cancer-free after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
surufatinib (a drug taken by mouth daily for 6 months after surgery)
What this could lead to
If it works, this could help prevent neuroendocrine tumors from coming back after surgery, giving patients more time without recurrence.
What could go wrong
This is a small, early-phase trial (35 people) with no results yet. The drug may not prevent recurrence and could cause side effects like any cancer medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS (TUMOURS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.